Colonización intestinal por enterococo resistente a la vancomicina en pacientes oncológicos con factores de riesgo / Intestinal colonization by vancomycin-resistant enterococci in cancer patients with risk factors

RESUMEN

Los objetivos del estudio fueron determinar la prevalencia de colonización intestinal por enterococo resistente a la vancomicina (EVR) en pacientes oncológicos con factores deriesgo y describir sus características clínicas y demográficas. Estudio longitudinal, realizado desde el 1 de diciembre del año 2008 al 30 de marzo del 2010, en =18 años de edad. 33 pacientes fueron incluidos. Se aislaron EVR en 94% (31/33), 39% (12/31)tenían entre 10 a 14 años. 58% (18/31) del sexo masculino, 21/31presentan Leucemia Linfoblástica aguda (LLA). Todos recibieron antibióticos previos, 90% (28/31) vancomicina. 84% (26/31) portaban catéteres venosos centrales (CVC), sometidosa cirugía 2/31, ARM 1/31. Se implementó precauciones de contacto. En conclusión, se observó alto porcentaje de colonización por EVR. CVC y uso de vancomicina predominaron. Es importante proseguir con la vigilancia, las medidas establecidas y el uso prudente de vancomicina.

ABSTRACT

The study objectives were to determine the prevalence of intestinal colonization by vancomycin-resistant enterococci(VRE) in cancer patients with risk factors and describe their clinical and demographic characteristics. A longitudinal study conducted between December 1, 2008 and March 30, 2010, in patients aged =18 years. A total of 33 patients were included. VRE were isolated in 94% (31/33), of whom 39% (12/31) were age 10—14 years. 58% (18/31) were male, and 21/31 presented acute lymphoblastic leukemia (ALL). All had previously received antibiotics, 90% (28/31) vancomycin. 84% (26/31) had central venous catheters (CVC), 2/31 had surgery, and 1/31 MV. Contact precautions were implemented. In conclusion, a highrate of VRE colonization was observed. CVC and use of vancomycin were predominant. It is important to continue the established measures, monitoring, and the prudent use of vancomycin.